Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423078 · ClinicalTrials.gov registry record · Phase 2
Window of Opportunity in Preserving Laryngeal Function Trial
A Phase 2 study, sponsored by Matthew Spector.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT07423078 is a Phase 2 study that is actively recruiting participants, run by Matthew Spector. The registered enrollment target is 87 participants.
The verdict
NCT07423078, a Phase 2 study, is actively recruiting participants, sponsored by Matthew Spector.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- RADIATION Radiation Therapy
- DRUG Toripalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2026-04-06 |
| Est. Completion | 2031-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07423078
The ClinicalTrials.gov registry entry for NCT07423078 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Spector, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT07423078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07423078 about?
NCT07423078 is a clinical study titled "Window of Opportunity in Preserving Laryngeal Function Trial". This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
What is the current status of trial NCT07423078?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2026-04-06. Estimated completion is 2031-04-30.
What interventions are being tested in trial NCT07423078?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION), Toripalimab (DRUG).
Who is sponsoring clinical trial NCT07423078?
This trial is sponsored by Matthew Spector, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.